Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0018681 (headache)
 56,091 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The cerebrovascular concomitants of migraine, initial vasoconstrictriction succeeded by vasodilatation, have long been considered the primary event in the pathogenesis of headache. In recent years, certain physicochemical concomitants of the attack have been identified, all involving blood platelets: these include hyperaggregability, decrease 5-hydroxytryptamine concentration and decreased monoamine oxidase activity. These changes may represent the response to a circulating humoral agent, deriving perhaps from the pulmonary vascular bed. The agent may not only bring about nonspecific damage of the kind described but be responsible for the cerebrovascular changes and stimulation of pain receptors characteristic of the disease. This circulating humoral agent may belong to the prostaglandin family.
 ...
PMID:Cerebrovascular changes in migraine: secondary manifestations of a circulating humoral agent? 29 Jul 40

The results of a study of the activity of platelet monoamine oxidase (MAO) in patients with migraine or with "Cluster headache" during the acute phases and after treatment with L-5-hydroxytryptophan are presented. MAO levels are higher in migraine subjects than in normals. There is, also, a clear difference between basal MAO levels in migraine sufferers and in Cluster Headache sufferers. The treatment with L-5-hydroxytryptophan tend to normalize MAO activity in the migraine patients, but does not change the MAO activity in cluster headache patients.
 ...
PMID:Monoamine oxidase activities in patients with migraine or with cluster headache during the acute phases and after treatment with L-5-hydroxytryptophan. 31 25

The best results in the prevention of migraine have so far been obtained with tricyclic antihistamine, anti-5HT drugs. Experimentation of dimethothiazine--already widely employed in the management of essential headache--in this field is reported. Results obtained in a double-blind trial with a placebo on randomised levels and on a large series evaluated with Pearson's scatter index showed that the drug was effective, especially in the prevention of classic migraine. It was also usuable during attacks and in the prevention of cluster headache. Good tolerance and the absence of side-effects suggest the adoption of a standard course of 60 mg/day for not less than 2 to 3-4 months. Other therapeutic courses may be alternated during the year.
 ...
PMID:[Use of dimethothiazine in the prevention of hemicrania]. 32 91

The effects and side-effects in migraine prophylaxis of placebo, Divascan (1-isopropylnoradrenochrome--5--monosemicarbazone) and pizotifen were compared in a double-blind cross-over study. The dosage was for Divascan 15 mg a day and for pizotifen 3 mg a day. Data from the last 6 weeks of each test period of 8 weeks were used to assess the effect of the treatment. Thirty patients entered the trial. Data from 28 patients treated with placebo and Divascan and 27 patients treated with pizotifen were used for final evaluation. Pizotifen significantly reduced the number of migraine attacks, headache index and the consumption of ergotamine. Divascan also seemed to have effect. The consumption of ergotamine was reduced compared with placebo and there was a reduction, although not significant, of headache frequency and headache index. Pizotifen gave significantly larger reduction in headache frequency and headache index than Divascan and signficantly more patients stated a preference for pizotifen compared with Divascan. A good or very good effect was reported by 11 per cent of the patients on placebo, 39 per cent on Divascan and 70 per cent on pizotifen. Pizotifen had frequent side-effects, mainly drowsiness and weight gain, whereas Divascan in this respect did not differ from placebo. Physical examinations and laboratory investigations did not show any significant changes, apart from weight gain.
 ...
PMID:A comparison between placebo, pizotifen and 1-isopropyl-3-hydroxy-5-semicarbazono-6-oxo-2.3.5.6-tetrahydroindol (Divascan) in migraine prophylaxis. 32 46

It was recently suggested that prostaglandins' release (especially PGE1 and PGF2alpha) play a key role in the development of the migrainous attack. Based on this hypothesis a therapeutic trial with flufenamic acid (a prostaglandin inhibitor of the fenamates group) was conducted during 1 year in 5 patients suffering from recurrent ophthalmoplegic migraine. We treated 25 migrainous attacks; in 22 of them the patients reported marked alleviation of the headaches and only in two occasions a partial third nerve palsy accompanied the attack.
 ...
PMID:Ophthalmoplegic migraine: amelioration by Flufenamic acid, a prostaglandin inhibitor. 33 Nov 78

74 patients with arterial circulatory disorders have been treated with calcitonin in low dosages (0.25-0.5 mg s.c. or i.m. twice to three times weekly). In 3 women with Raynaud phenomenon in sclerodermia, previously refractory necroses of the finger-tips were cured. One woman with Raynaud disease became symptomfree. Marked improvements in the results of ergometric tests were observed in 8 out of 22 patients with intermittent claudication of the lower extremities. In 12 out of 31 patients with refractory angina pectoris, the attacks were practically eliminated. Remission of headaches of vascular origin was obtained in 6 out of 17 cases. Attacks of migraine were terminated in the incipient stage by treatment with 0.25 mg Cibacalcin.
 ...
PMID:[Treatment possibilities of arterial circulatory disorders using calcitonin]. 33 77

Evidence that a blunt head injury can engender a migrainous state in susceptible individuals is provided by a series of 13 patients who developed recurring attacks of classic migraine after suffering such injury. Among a group of patients with post-traumatic headache of more than one year's standing, the preponderant type of headache was found to be of the migrainous variety. The significance of these findings is discussed.
 ...
PMID:Migraine as a sequela of blunt head injury. 33 81

In a double-blind crossover trial of two 12-week treatment periods with a 4-week treatment free interval, to which 21 patients were admitted, there was no statistically significant difference between clonidine 75 microgram twice daily and placebo in the total number of headache days, migraine indices, duration of attacks, number of severe attacks and consumption of acute attack treatment. However, there was a marked reduction in number of headache days, migraine indices, duration of attacks and consumption of acute attack treatment during the second treatment period compared to the first treatment period, regardless of the treatment regime. This was presumably a result of prolonged treatment and frequent attention and not an effect of the active drug. 32 patients entered the trial, but 11 dropped out. Of the 21 patients completing the trial, 16 were women; the median age was 34 years (range 17-54 years) and the median duration of headaches 12 years (range 1-40 years). Only mild side-effects were registered and no laboratory abnormalities were seen.
 ...
PMID:Prophylactic treatment of migraine with clonidine. A controlled clinical trial. 33 59

Severe migraine attacks in 47 patients who were unresponsive to clonidine hydrochloride were treated with 1.5 mg pizotifen for a mean period of 6 month. The attack incidence, duration and severity were more than halved in 64% (30 patients), 25% becoming headache-free. Side-effects were not serious but weight gain was a problem in some subjects. Pizotifen administration allowed withdrawal of methysergide and ergotamine compounds without rebound headache. It appeared specially remedial in those whose migraine could be triggered by dietary factors. Follow-up 22 patients at 15 months confirmed these findings, 48.6% remaining 'improved' by the criteria of the trial (28% headache-free), and underlined the marked reduction in symptomatic drugs required and the absence of toxicity in long-term treatment.
 ...
PMID:Use of pizotifen in severe migraine: a long-term study. 34 Jan 39

The majority of migraine attacks are associated with gastrointestinal symptoms which add considerably to the distress and inconvenience caused by the headache. When salicylate absorption from effervescent aspirin tablets was studied during migraine, the rate of absorption was found to be reduced relative to that found in non-migrainous volunteers and in the same patients when headache-free. There is evidence that this reduced rate of absorption is caused by gastrointestinal stasis and reduced rate of gastric emptying. Patients in whom aspirin absorption was delayed were more likely to take longer to respond and to require additional treatment. Metoclopramide, which increases gastric emptying rate, has been shown to improve the rate of absorption of aspirin during migraine and also increase the rate of recovery from the attack and avoid the need for additional treatment; effects which were not shown by thiethylperazine. It is likely that delayed absorption during migraine affects some drugs other than aspirin, such as ergotamine, and it is therefore recommended that the most rapidly absorbable formulation should be used. If such treatment is ineffective, metoclopramide may be a useful addition and should be tried before resorting to other routes of administration.
 ...
PMID:Migraine and drug absorption. 35 37


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>